JP2019517540A - アルツハイマー病を治療する方法 - Google Patents

アルツハイマー病を治療する方法 Download PDF

Info

Publication number
JP2019517540A
JP2019517540A JP2018563815A JP2018563815A JP2019517540A JP 2019517540 A JP2019517540 A JP 2019517540A JP 2018563815 A JP2018563815 A JP 2018563815A JP 2018563815 A JP2018563815 A JP 2018563815A JP 2019517540 A JP2019517540 A JP 2019517540A
Authority
JP
Japan
Prior art keywords
subject
antibody
body weight
amount
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018563815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517540A5 (enExample
Inventor
ブレンドン フィリップ ブート，
ブレンドン フィリップ ブート，
ジェフリー ジョセフ セヴィニー，
ジェフリー ジョセフ セヴィニー，
レスリー ルジーン ウイリアムズ，
レスリー ルジーン ウイリアムズ，
Original Assignee
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー, バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー filed Critical バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
Publication of JP2019517540A publication Critical patent/JP2019517540A/ja
Publication of JP2019517540A5 publication Critical patent/JP2019517540A5/ja
Priority to JP2022129326A priority Critical patent/JP2022145965A/ja
Priority to JP2025124966A priority patent/JP2025160337A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018563815A 2016-06-07 2017-06-06 アルツハイマー病を治療する方法 Withdrawn JP2019517540A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129326A JP2022145965A (ja) 2016-06-07 2022-08-15 アルツハイマー病を治療する方法
JP2025124966A JP2025160337A (ja) 2016-06-07 2025-07-25 アルツハイマー病を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129326A Division JP2022145965A (ja) 2016-06-07 2022-08-15 アルツハイマー病を治療する方法

Publications (2)

Publication Number Publication Date
JP2019517540A true JP2019517540A (ja) 2019-06-24
JP2019517540A5 JP2019517540A5 (enExample) 2020-07-09

Family

ID=59067640

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563815A Withdrawn JP2019517540A (ja) 2016-06-07 2017-06-06 アルツハイマー病を治療する方法
JP2022129326A Withdrawn JP2022145965A (ja) 2016-06-07 2022-08-15 アルツハイマー病を治療する方法
JP2025124966A Pending JP2025160337A (ja) 2016-06-07 2025-07-25 アルツハイマー病を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022129326A Withdrawn JP2022145965A (ja) 2016-06-07 2022-08-15 アルツハイマー病を治療する方法
JP2025124966A Pending JP2025160337A (ja) 2016-06-07 2025-07-25 アルツハイマー病を治療する方法

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553329A (ja) * 2019-10-22 2022-12-22 バイオジェン・エムエイ・インコーポレイテッド アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
EP3946603A1 (en) 2019-03-26 2022-02-09 Janssen Pharmaceutica NV Antibodies to pyroglutamate amyloid-ss and uses thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
CA3186614A1 (en) 2020-07-23 2022-01-27 Michael SKOV Anti-abeta antibodies
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
TW202313111A (zh) * 2021-06-07 2023-04-01 美商百健Ｍａ公司 治療阿茲海默症之方法
WO2023055733A1 (en) * 2021-09-30 2023-04-06 The Scripps Research Institute Compounds for reducing neuroinflammation
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120233A1 (en) * 2014-02-08 2015-08-13 Genentech, Inc. Methods of treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01075B (me) * 2006-07-14 2012-10-20 Ac Immune Sa Antitijela
PT2436696T (pt) 2007-01-05 2017-08-21 Univ Zuerich Anticorpo anti-beta-amiloide e usos do mesmo
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
BR112015008347B1 (pt) * 2012-10-15 2023-12-26 Medimmune Limited Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo
AU2013354968A1 (en) * 2012-12-07 2015-07-16 Joseph Arndt A method of reducing brain amyloid plaques using anti-AB antibodies
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120233A1 (en) * 2014-02-08 2015-08-13 Genentech, Inc. Methods of treating alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALZHEIMER'S & DEMENTIA, vol. 9, JPN6021020509, 2013, pages 105 - 115, ISSN: 0004888985 *
JACOPO C DIFRANCESCO: "ANTI-Aβ AUTOANTIBODIES IN AMYLOID RELATED IMAGING ABNORMALITIES (ARIA): CANDIDATE 以下備考", FRONTIERS IN NEUROLOGY, vol. 6, JPN5019005383, 25 September 2015 (2015-09-25), pages 1 - 6, ISSN: 0004888984 *
鹿児島市医報, vol. 第51巻, 第6号, JPN6022014696, 2012, pages 8 - 9, ISSN: 0004888986 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553329A (ja) * 2019-10-22 2022-12-22 バイオジェン・エムエイ・インコーポレイテッド アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Also Published As

Publication number Publication date
EP3464350A1 (en) 2019-04-10
JP2025160337A (ja) 2025-10-22
AU2017276656A1 (en) 2018-12-13
MA45149A (fr) 2019-04-10
IL263433A (en) 2019-01-31
CN109476730A (zh) 2019-03-15
CA3026598A1 (en) 2017-12-14
US20200308259A1 (en) 2020-10-01
US20220281963A1 (en) 2022-09-08
JP2022145965A (ja) 2022-10-04
CN114931635A (zh) 2022-08-23
CN114796481A (zh) 2022-07-29
BR112018075300A2 (pt) 2019-04-30
AU2024216442A1 (en) 2024-10-17
MX2018015022A (es) 2019-08-14
WO2017211827A1 (en) 2017-12-14
KR20230165883A (ko) 2023-12-05
KR20190021311A (ko) 2019-03-05
IL263433B1 (en) 2023-11-01
IL263433B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
US20220281963A1 (en) Methods for treating alzheimer's disease
JP2023011002A (ja) アルツハイマー病の治療法
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
JP2024540294A (ja) アルツハイマー病を治療するための方法
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2025182058A (ja) アルツハイマー病の治療法
TW202313111A (zh) 治療阿茲海默症之方法
NZ788486A (en) Methods for treating Alzheimer's disease
WO2025064824A1 (en) Methods for treating alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220912

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221007

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221012

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221129